MGMarina Green-Gomez

Marina Green-Gomez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marina Green-Gomez has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • John M. Nolan

    Nutrition Research Centre Ireland, School of Health Science, South East Technological University, X91 K236 Waterford, Ireland

    4 shared publications
  • Aldo Torre

    Gastroenterology Department ABC Medical Center Mexico City Mexico

    1 shared publication
  • Alfonso Prado-Cabrero

    Nutrition Research Centre Ireland, School of Health Science, Carriganore House, Waterford Institute of Technology, West Campus, Waterford X91 K236, Ireland

    1 shared publication
  • Andrés Duarte‐Rojo

    Division of Gastroenterology and Hepatology University of Arkansas for Medical Sciences (UAMS) Little Rock AR USA

    1 shared publication
  • Astrid Ruiz‐Margáin

    Liver Clinic Department of Gastroenterology Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán” México D.F Tlalpan México

    1 shared publication
  • Carlos Cantú‐Brito

    Department of Neurology Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán” México D.F Tlalpan México

    1 shared publication

Latest Publications

  • Open Access

    The Impact of Formulation on Lutein, Zeaxanthin, and meso-Zeaxanthin Bioavailability: A Randomised Double-Blind Placebo-Controlled Study

    by Marina Green-Gomez, Alfonso Prado-Cabrero, Rachel Moran, Tommy Power, Laura G. Gómez-Mascaraque, Jim Stack, John M. Nolan

    Lutein (L), zeaxanthin (Z), and meso-zeaxanthin (MZ) have been the focus of research and commercial interest for their applications in human health. Research into formulations to enhance their bioavailability is merited. This 6 month randomised placebo-controlled trial involving 81 healthy volunteers compared the bioavailability of different formulations of free L, Z, and MZ in sunflower or omega-3 oil versus L, Z, and MZ diacetates (Ld, Zd, and MZd) in a micromicellar formulation. Fasting serum carotenoids, macular pigment, and skin carotenoid score were analysed at baseline and 6 months. Serum L, Z, and MZ concentrations increased in all active interventions compared to placebo (p < 0.001 to p = 0.008). The diacetate micromicelle formulation exhibited a significantly higher mean response in serum concentrations of Z and MZ compared to the other active interventions (p = 0.002 to 0.019). A micromicellar formulation with solubilised Z and MZ diacetates is a promising technology advancement that enhances the bioavailability of these carotenoids when compared to traditional carotenoid formulations (ISRCTN clinical trial registration number: ISRCTN18206561).


  • Open Access

    Standardizing the Assessment of Macular Pigment Using a Dual-Wavelength Autofluorescence Technique

    by Marina Green-Gomez, Paul S. Bernstein, Christine A. Curcio, Rachel Moran, Warren Roche, John M. Nolan

    Purpose: It is essential to have an appropriate measure to assess macular pigment (MP) that can provide an accurate, valid, and reliable representation of the MP within the macula. The aim of this study was to describe and introduce MP optical volume (MPOV) as an optimal value for reporting MP. Methods: Three hundred ninety-three subjects were analyzed using the Heidelberg Spectralis with the investigational MP optical density (MPOD) module to measure MPOV and MPOD at four foveal eccentricities (0.23°, 0.51°, 0.98°, 1.76° [7° as reference point]). Lutein (L) and zeaxanthin (Z) dietary intake and serum concentrations were evaluated. Results: MPOV mean was 5094 (95%CI, 4877–5310); range: 527 to 10,652. MPOV was inversely correlated with body mass index and positively correlated with education (r = −0.156, P = 0.002 and r = 0.124, P = 0.014, respectively). Serum concentrations of L and Z were positively correlated with MPOV (r = 0.422, P < 0.001 and r = 0.285, P < 0.001, respectively). MPOV was positively correlated to MPOD at all measured eccentricities, with the strongest agreement at 1.76° (r = 0.906, P < 0.001). Serum concentrations of L and Z, BMI, education, and age (P < 0.001) were found to be significant predictors of MPOV. Conclusions: The Spectralis MPOV measurement provided a comprehensive and detailed evaluation of the MP profile. The Spectralis MPOV should be considered a preferred metric for the assessment of MP. Translational Relevance: Applying a standardized method for the assessment and report of MP will allow to fully derive meaning from observational studies and to successfully implement this MP measurement technique in research and clinical settings.


  • Cerebral haemodynamics in cirrhotic patients with hepatic encephalopathy

    by Ricardo U. Macías‐Rodríguez, Andrés Duarte‐Rojo, Carlos Cantú‐Brito, Tilman Sauerbruch, Astrid Ruiz‐Margáin, Jonel Trebicka, Marina Green‐Gómez, Jorge B. Díaz Ramírez, Manuel Sierra Beltrán, Misael Uribe‐Esquivel, et al.

    Background & Aims: Factors other than elevated levels of ammonia may be implicated in hepatic encephalopathy (HE) pathophysiology, including abnormal cerebral haemodynamics. Transcranial Doppler ultrasonography (TCD) evaluates cerebrovascular structural integrity and reactivity, through pulsatility index (PI) and breath‐holding index (BHI) respectively. The aim of this study was to evaluate cerebral haemodynamics by TCD in patients with compensated and decompensated cirrhosis, and patients with and without HE.Methods: We studied 90 subjects by TCD measuring PI and BHI in the middle cerebral artery: 30 with cirrhosis and no HE, 30 with cirrhosis and low‐grade HE and 30 healthy subjects. Critical flicker frequency, psychometric hepatic encephalopathy score and West‐Haven criteria were performed to assess MHE and HE respectively.Results: Pulsatility index increased in decompensated cirrhotics (Child ≥ 7) when compared with compensated cirrhotics and healthy subjects [median (IQR) 1.07 (0.95–1.21) vs 0.90 (0.83–1.05) vs 0.87 (0.78–0.96); P < 0.001]. A reverse relationship was observed for BHI among the three groups [0.82 (0.45–1.11) vs 1.20 (0.82–1.52) vs 1.28 (1.06–1.68); P < 0.001]. Similar findings were observed in decompensation [model for end‐stage liver disease (MELD) score ≥14]. Patients with HE showed higher PI and lower BHI [1.05 (1.00–1.16) and 0.89 (0.59–1.15)], when compared with patients without HE [0.96 (0.83–1.13) and 1.00 (0.60–1.53)] or controls [0.87 (0.78–0.96) and 1.28 (1.06–1.68)] (P < 0.001 for PI, and P = 0.007 for BHI). In multivariate regression models, only PI predicted HE, but it was outperformed by MELD‐sodium and tumour necrosis factor‐alpha.Conclusions: These results indicate that cerebral haemodynamics are altered in patients with cirrhosis, in relation to severity of disease and HE. Findings on impaired PI and BHI suggest that structural vascular damage and loss of vascular autoregulation are implicated in the pathophysiology of HE.